OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE

被引：0
|
作者：
Ong, Shin Yeu [1 ]
Krisnadi, Cindy [1 ]
Wang, Samuel Sherng Young [1 ]
Chen, Yun Xin [1 ]
Seng, Michaela Su-fern [2 ]
Soh, Shui Yen [2 ]
Chan, Esther Hian Li [3 ]
Hwang, William Ying Khee [1 ]
Ho, Aloysius Yew Leng [1 ]
Lim, Francesca Lorraine Wei Inng [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
[2] KK Womens & Childrens Hosp, Singapore, Singapore
[3] Natl Univ Canc Inst, Singapore, Singapore
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P120
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [1] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma
    Stock, Sophia
    Bucklein, Veit L.
    Blumenberg, Viktoria
    Magno, Giulia
    Emhardt, Alica-Joana
    Holzem, Alessandra M. E.
    dos Santos, David M. Cordas
    Schmidt, Christian
    Griesshammer, Stefanie
    Frolich, Lisa
    Kobold, Sebastian
    von Bergwelt-Baildon, Michael
    Rejeski, Kai
    Subklewe, Marion
    HEMASPHERE, 2025, 9 (01):
  • [2] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 15 - 17
  • [3] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
    Sano, Dahlia
    Nastoupil, Loretta J.
    Fowler, Nathan H.
    Fayad, Luis
    Hagemeister, F. B.
    Lee, Hun Ju
    Samaniego, Felipe
    Wang, Michael
    Rodriguez, Maria Alma
    Iyer, Swaminathan P.
    Parmar, Simrit
    Steiner, Raphael
    Nair, Ranjit
    Adkins, Sherry
    Arafat, Sara
    Rao, Ahalya
    Vallejo, Liliana
    Hawkins, Misha
    Chen, Yiming
    Westin, Jason R.
    Neelapu, Sattva S.
    BLOOD, 2018, 132
  • [4] Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma
    Wei, Jia
    Xiao, Min
    Mao, Zekai
    Wang, Na
    Li, Chunrui
    Cao, Yang
    Sun, Weimin
    Xiao, Yi
    Gu, Chaojiang
    Zhang, Shangkun
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    Huang, Liang
    BLOOD, 2020, 136
  • [5] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
  • [6] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
    Huang, Lefu
    Li, Jingjing
    Yang, Junfang
    Zhang, Xian
    Zhang, Min
    He, Jiujiang
    Zhang, Gailing
    Li, Wenqian
    Wang, Hui
    Li, Jianqiang
    Lu, Peihua
    CELLS, 2022, 11 (24)
  • [7] Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy
    Colton, Meryl
    Purev, Enkhtsetseg
    Haverkos, Bradley
    Bair, Steven
    Jasem, Jagar
    Jacob, Allison
    Kamdar, Manali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (11): : 778 - 782
  • [8] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
    Chow, Victor A.
    Shadman, Mazyar
    Gopal, Ajay K.
    BLOOD, 2018, 132 (08) : 777 - 781
  • [9] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Gideon, Jacklyn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601
  • [10] CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
    Wei, Guoqing
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Liu, Yandan
    Liang, Bin
    Wang, Xiujian
    Xu, Huijun
    Cui, Jiazhen
    Wu, Wenjun
    Zhao, Kui
    Nagler, Arnon
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (09) : 1061 - 1070
12345